By Counterforce Health Team in Garadacimab (anti-FXIIa) — FDA-approved 2025 —

How to Get Garadacimab (Andembry) Covered by Blue Cross Blue Shield in Washington: Complete Prior Authorization and Appeals Guide

Answer Box: Getting Garadacimab Covered by BCBS in Washington

Garadacimab (Andembry) requires prior authorization from Blue Cross Blue Shield plans in Washington. Submit a formulary exception request with confirmed HAE diagnosis (ICD-10 D84.1), lab results showing low C4 and C1-INH levels, and documentation of prior therapy failures. If denied, appeal internally within 180 days, then request external review through Washington's Office of Insurance Commissioner. First step: Have your provider submit the Pharmacy Exception Request Form with complete clinical documentation.

Table of Contents

  1. Coverage Requirements Overview
  2. Step-by-Step: Fastest Path to Approval
  3. Medical Necessity Documentation
  4. Coding and Billing Essentials
  5. Common Denial Reasons & Solutions
  6. Appeals Process in Washington
  7. Cost Support Options
  8. When to Contact Regulators
  9. FAQ

Coverage Requirements Overview

Requirement Details Where to Verify Source
Prior Authorization Required for all BCBS plans Member portal or provider services Premera PA Requirements
Formulary Status Non-formulary (exception needed) Plan-specific drug list LifeWise Drug Approval
Diagnosis Code ICD-10 D84.1 (Complement defects) Provider documentation Aetna HAE Policy
HCPCS Code J9256 (effective Jan 1, 2026) CMS HCPCS updates CMS HCPCS Applications
Age Requirement 12 years and older FDA prescribing information FDA Label
Appeal Timeline 180 days from denial Washington state law WA Insurance Appeals

Step-by-Step: Fastest Path to Approval

1. Confirm HAE Diagnosis and Lab Results

Who: Healthcare provider
Timeline: Before PA submission
Required: C4 level below normal, plus C1-INH antigenic or functional level below normal, or genetic confirmation of HAE-causing mutation

2. Gather Prior Therapy Documentation

Who: Provider and patient
Timeline: 1-2 weeks before submission
Required: Records of previous HAE treatments tried, dates of use, reasons for discontinuation (inefficacy, adverse effects, contraindications)

3. Submit Formulary Exception Request

Who: Healthcare provider
Timeline: Standard 72 hours, urgent 24 hours
How: Fax completed exception form to plan-specific number (Premera: 888-260-9836)

4. Include Complete Clinical Documentation

Who: Provider
Timeline: With initial submission
Required: HAE attack frequency, weight-based dosing rationale, treatment goals, monitoring plan

5. Follow Up on Decision

Who: Patient or provider
Timeline: Within decision timeframe
Action: Contact member services if no response within stated timeline

6. Appeal if Denied

Who: Patient with provider support
Timeline: Within 180 days of denial
Process: Internal appeal first, then external review if needed

7. Request External Review if Necessary

Who: Patient
Timeline: Within 180 days of final internal denial
Contact: WA Office of Insurance Commissioner at 1-800-562-6900

Medical Necessity Documentation

Clinician Corner: Essential Documentation Elements

Your medical necessity letter should include these evidence-based components:

Clinical History:

  • Confirmed HAE diagnosis with lab values (C4, C1-INH levels)
  • Attack frequency and severity documentation
  • Impact on quality of life and daily functioning
  • Emergency department visits or hospitalizations due to HAE

Prior Therapy Documentation:

  • Specific medications tried (lanadelumab, berotralstat, C1-INH products)
  • Duration of each trial
  • Reasons for discontinuation with dates
  • Adverse effects or contraindications experienced

Treatment Rationale:

  • Why garadacimab is medically necessary
  • Expected clinical outcomes
  • Dosing schedule (200mg monthly subcutaneous)
  • Monitoring plan and follow-up schedule

Supporting Evidence:

Counterforce Health specializes in creating comprehensive medical necessity letters that align with payer requirements and incorporate the most current clinical evidence. Their platform analyzes denial patterns and crafts targeted appeals that address specific payer concerns while maintaining clinical accuracy.

Coding and Billing Essentials

ICD-10 Diagnosis Coding

Primary Code: D84.1 (Defects in the complement system)
Documentation: Must include specific HAE subtype if known and lab confirmation

HCPCS/J-Code Information

Current Code: J9256 (Injection, garadacimab-gxii, 200 mg)
Effective Date: January 1, 2026
Previous Temporary Code: C9399 (replaced by J9256)

Dosing and Units Calculation

  • Standard Dose: 200 mg monthly (1 prefilled pen)
  • Billing Units: 1 unit = 200 mg dose
  • Quantity Limits: Typically 1 pen per 30 days
  • Administration: Subcutaneous injection (use JB modifier if multiple routes exist)

Medical vs. Pharmacy Benefit

Medical Benefit Billing:

  • Uses HCPCS codes
  • Subject to medical necessity review
  • May require site-of-care restrictions

Pharmacy Benefit Billing:

  • Uses NDC codes
  • Subject to formulary restrictions
  • Dispensing limits apply
Tip: Verify which benefit applies with your specific BCBS plan, as specialty injectables may be covered under either pathway.

Common Denial Reasons & Solutions

Denial Reason Solution Strategy Required Documentation
Lack of HAE confirmation Submit complete lab workup C4, C1-INH levels, genetic testing if available
Step therapy required Document prior failures Detailed records of lanadelumab, berotralstat trials
Non-formulary status Request formulary exception Medical necessity letter with contraindications
Quantity limit exceeded Justify dosing frequency Weight-based calculations, attack prevention data
"Not medically necessary" Provide clinical evidence Attack logs, quality of life impact, ER visits
Missing REMS documentation Complete training requirements Provider certification, patient education records

Appeals Process in Washington

Internal Appeals (Required First Step)

Level 1 Internal Appeal:

  • Timeline: File within 180 days of denial
  • Decision Time: 30 days (15 days for urgent)
  • How to File: Written request to address on denial letter
  • Required: Original denial letter, new supporting evidence

Level 2 Internal Appeal (if applicable):

  • Timeline: 180 days from Level 1 denial
  • Process: Similar to Level 1 with additional documentation

External Review (Independent Review Organization)

Eligibility: After exhausting internal appeals or if insurer fails to respond timely
Timeline: Request within 180 days of final internal denial
Decision Time: 20 days standard, 72 hours expedited
Cost: Free to consumer
Binding: Yes, on the insurance company

How to Request:

  1. Contact Washington Office of Insurance Commissioner at 1-800-562-6900
  2. Submit request with all documentation
  3. IRO assigned automatically from state registry
  4. Independent medical experts review case
Note: Washington's external review process is particularly effective for rare disease medications, as the state has access to specialists at major medical centers who often serve as IRO reviewers.

Cost Support Options

Manufacturer Support Programs

  • CSL Behring Patient Support: Contact manufacturer directly for copay assistance and patient access programs
  • Specialty Pharmacy Networks: Many offer care coordination and financial counseling

Additional Resources

  • State Pharmaceutical Assistance Programs: Check Washington state resources for eligible patients
  • Foundation Grants: Organizations supporting rare disease patients may offer assistance
  • Clinical Trial Opportunities: Consider if standard therapy options are exhausted

When patients face coverage challenges, Counterforce Health provides comprehensive support by analyzing denial letters, identifying the specific basis for denial, and creating targeted appeals that address payer concerns while advocating for patient access to necessary medications.

When to Contact Regulators

Contact the Washington Office of Insurance Commissioner if:

  • Your insurer fails to respond within required timelines
  • You believe the denial violates state or federal law
  • The appeals process is not being followed properly
  • You need assistance understanding your rights

Contact Information:

  • Phone: 1-800-562-6900
  • Website: insurance.wa.gov
  • Services: Free consumer assistance, complaint filing, appeals guidance

FAQ

How long does BCBS prior authorization take for garadacimab in Washington? Standard requests: 72 hours. Urgent requests: 24 hours. If no response within this timeframe, contact member services immediately.

What if garadacimab is non-formulary on my BCBS plan? Request a formulary exception using your plan's pharmacy exception form. Include documentation of medical necessity and prior therapy failures.

Can I request an expedited appeal in Washington? Yes, if your health could be in serious jeopardy without the medication. Expedited external reviews are decided within 72 hours.

Does step therapy apply if I've tried HAE medications outside Washington? Yes, prior therapy documentation from any location is valid. Ensure you have complete records including dates, dosages, and reasons for discontinuation.

What happens if my external review is denied? The external review decision is binding on the insurer. If denied, you may still contact the Insurance Commissioner for guidance or consider legal consultation.

Are there age restrictions for garadacimab coverage? FDA approval is for patients 12 years and older. BCBS plans typically follow FDA labeling for age requirements.

How do I find my specific BCBS plan's formulary? Log into your member portal or call the customer service number on your insurance card. Each BCBS plan maintains its own formulary list.

Can my doctor request a peer-to-peer review? Yes, most BCBS plans allow providers to request peer-to-peer discussions with medical directors during the PA or appeal process.

From our advocates: We've seen numerous HAE patients successfully obtain coverage for newer prophylactic treatments through Washington's external review process. The key is comprehensive documentation of attack frequency, prior therapy failures, and impact on daily life. While each case is unique, thorough preparation and understanding of the appeals process significantly improve outcomes.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Insurance coverage decisions depend on individual circumstances and plan terms. Always consult with your healthcare provider and insurance company for guidance specific to your situation. For additional support with complex appeals, consider consulting with organizations like Counterforce Health that specialize in insurance coverage advocacy.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.